Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Akari Therapeutics Plc, a public company incorporated under the laws of England and Wales, for the month of September 2023. The report was issued on September 5, 2023, to announce a specific regulatory compliance milestone regarding its listing on the Nasdaq stock exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory status rather than a financial statement.
Material Changes
The primary material change reported is the Company's regained compliance with the Nasdaq minimum bid price requirement. This status was achieved because the Company's American Depository Shares (ADS) maintained a closing bid price of $1.00 per share or greater for 10 consecutive business days.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the context of the Nasdaq compliance issue. The document serves solely to incorporate the press release regarding the bid price compliance by reference.
Key Facts for Investor Verification
- Company regained compliance with Nasdaq minimum bid price requirements as of September 5, 2023.
- Compliance was triggered by ADS closing bid prices of $1.00 or higher for 10 consecutive business days.
- No financial performance data is included in this specific filing.
- The press release detailing this announcement is attached as Exhibit 99.1.